The STAR trial is investigating Semaglutide, a GLP-1 analogue, as a potential treatment for Alcohol Use Disorder (AUD). Given the limited current pharmacotherapy options for AUD, a successful outcome could position Semaglutide as a novel therapeutic alternative in a market with significant unmet needs. The trial's design includes a robust behavioral therapy component, enhancing its appeal. If proven effective, this could lead to expanded indications for Semaglutide beyond its current use in diabetes and obesity, potentially increasing market share and revenue streams for the sponsor, the National Institute on Drug Abuse (NIDA). The competitive landscape includes existing AUD treatments such as naltrexone and acamprosate, but Semaglutide's unique mechanism may provide a differentiated offering. Diligence should focus on the trial's safety and tolerability outcomes, as adverse events could impact market acceptance.